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Abstract
The urokinase plasminogen activator receptor (uPAR) plays a role in tumor progression and has been proposed as a target
for the treatment of cancer. We recently described the development of a novel humanized monoclonal antibody that
targets uPAR and has anti-tumor activity in multiple xenograft animal tumor models. This antibody, ATN-658, does not
inhibit ligand binding (i.e. uPA and vitronectin) to uPAR and its mechanism of action remains unclear. As a first step in
understanding the anti-tumor activity of ATN-658, we set out to identify the epitope on uPAR to which ATN-658 binds.
Guided by comparisons between primate and human uPAR, epitope mapping studies were performed using several
orthogonal techniques. Systematic site directed and alanine scanning mutagenesis identified the region of aa 268–275 of
uPAR as the epitope for ATN-658. No known function has previously been attributed to this epitope Structural insights into
epitope recognition were obtained from structural studies of the Fab fragment of ATN-658 bound to uPAR. The structure
shows that the ATN-658 binds to the DIII domain of uPAR, close to the C-terminus of the receptor, corroborating the
epitope mapping results. Intriguingly, when bound to uPAR, the complementarity determining region (CDR) regions of
ATN-658 closely mimic the binding regions of the integrin CD11b (aM), a previously identified uPAR ligand thought to be
involved in leukocyte rolling, migration and complement fixation with no known role in tumor progression of solid tumors.
These studies reveal a new functional epitope on uPAR involved in tumor progression and demonstrate a previously
unrecognized strategy for the therapeutic targeting of uPAR.
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Introduction
Metastasis and angiogenesis share many common phenotypic
features that lead to the invasion and migration of tumor and
endothelial cells. These include the up-regulation of protease and
integrin expression, the loss of cell-cell and cell-matrix contacts, an
increase in responsiveness to growth and differentiation factors,
and the remodeling of extracellular matrix (ECM) and basement
PLOS ONE | www.plosone.org 1 January 2014 | Volume 9 | Issue 1 | e85349membrane (BM) [1,2]. The urokinase plasminogen activator (uPA)
system, comprised of uPA, a specific cell surface receptor for uPA
(uPAR), and serpin inhibitors of uPA such as plasminogen
activator inhibitor-1 (PAI-1), plays a central role in many of these
activities [3–6]. The activity of this system is responsible for
initiating cascades that result in the activation of plasminogen and
several pro-metalloproteases (proMMPs) [7,8], release and pro-
cessing of latent growth factors deposited in the ECM such as
FGF-2, VEGF, HGF, and TGF-b [9–12] and remodeling
components of the ECM such as vitronectin and fibronectin
[13,14]. These activities are generally mediated by the proteolytic
function of uPA when bound to uPAR, can be modulated by the
inhibition of uPA by PAI-1, and occur in the extracellular
environment. In addition, uPAR also interacts with many other
ligands in addition to uPA including several integrins such as a5b1,
a3b1, and a5b3 [15–17], as well as other cell surface and ECM
ligands including vitronectin and G protein–coupled receptors [6].
Several of these interactions have been demonstrated to be
important for tumor cell survival, invasion, and angiogenesis [6],
and involve uPAR-dependent signaling.
For these reasons, uPAR has been proposed as a therapeutic
target for the treatment of cancer. However, despite an abundance
of literature demonstrating the importance of uPAR in the
progression of most solid cancers, including breast [18], colon
[19], prostate [20], pancreatic [21], ovarian [22], lung [23], and
brain [24] as well as several hematologic malignancies such as
acute leukemia and myeloma [25], no uPAR targeted therapeutic
agent has been developed or evaluated in cancer clinical trials to
date. A number of antibodies that directly inhibit the binding of
uPA to uPAR have been proposed and tested in pre-clinical studies
but most of these have only demonstrated modest antitumor
activity and were therefore never advanced into the clinic.
Recently, we identified and developed a novel uPAR targeted
monoclonal antibody that demonstrates robust antitumor effects in
a number of different animal tumor models but does not block the
binding of uPA to uPAR [22,26–28]. This antibody, ATN-658,
has several unique attributes that differentiate it from previous
uPAR targeted approaches. A key feature is that ATN-658 is that
it does not block uPA binding to uPAR and is able to bind to
uPAR even when it is occupied by uPA, but nevertheless inhibits
migration and invasion in vitro [22,27]. ATN-658 has no effect on
uPA mediated plasminogen activation but does have a number of
effects on signaling pathways and the expression of various genes
implicated in tumor progression when evaluated in models of
prostate and ovarian cancer in vitro and in vivo [22,27]. One of the
most striking observations with ATN-658 is that the pharmaco-
logical targeting of uPAR by this antibody leads to robust
antitumor effects in a broad range of solid tumor xenograft models
[22,26–28]. Antitumor effects have been observed regardless of
tumor histology in these models and in addition to inhibition of
metastasis in vivo, as would be predicted for an uPAR targeted
agent, ATN-658 is also able to inhibit tumor proliferation and
induce apoptosis [22,26,28]. However, the structural and mech-
anistic basis for these antitumor effects remain unclear.
In order to address this issue, we characterized the epitope on
uPAR to which ATN-658 binds. The epitope for ATN-658 was
initially mapped using site-directed mutagenesis and confirmed by
a novel deuterium exchange mass spectrometry technique (H/D-
exchange mass spectrometry, ExSAR). This epitope was deter-
mined to be an epitope for which no function in uPAR has
previously been described. In addition, we determined the crystal
structures of the ATN-658 Fab fragment alone and in complex
with uPAR, the amino terminal (uPAR binding domain) of uPA
(ATF), and the somatomedin B domain (SMB) of vitronectin. The
ATN-658 Fab binds to the DIII of uPAR, consistent with the
epitope mapping results. The epitope on uPAR for ATN-658 is
close to the C-terminus, and has no overlap with the urokinase and
vitronectin binding sites. This study also revealed structural
homology between the ATN-658 CDR loops and the uPAR
binding region of integrin aM. Moreover, we showed that ATN-
658 binding blocks the association of another integrin, a5b1, to
uPAR and thus impairs integrin a5b1-mediated adhesion to
extracellular matrix. These results suggest a previously unrecog-
nized mechanism by which uPAR may function in tumor
progression and a novel epitope for the therapeutic targeting of
this receptor.
Materials and Methods
Cell Lines
Human tumor lines PC-3 (prostate adenocarcinoma), HeLa
(cervical carcinoma), and human lung cancer cell line H1299 were
obtained from the American Type Culture Collection (Manassas,
VA). Both cell lines were cultured in Dulbecco’s modified
minimum Eagle’s medium supplemented with 10% fetal bovine
serum and penicillin-streptomycin. Mouse tumor cell line B-16
(melanoma), dog osteosarcoma (D-17) and immortalized African
green monkey (AGM) kidney cells (COS-1) were verified to
express uPAR by RT-PCR and western blot using a rabbit
polyclonal uPAR antiserum (rD2D3) known to cross-react with
uPAR from multiple species as previously described [29]. uPAR
expressing cells were then used to evaluate the ability of ATN-658
to cross-react with various non-human uPAR. Both recombinant
soluble uPAR (suPAR, residues 1–277) and ATF (amino acid
residues 1–143 of uPA) were produced in Drosophila S2 cells as
secreted proteins E.Coli [31].
Characterization of monoclonal antibody ATN-658
ATN-658 was raised against a chymotryptic fragment of soluble
uPAR (suPAR) comprising DIIDIII (aa 88–283 of mature uPAR)
expressed in Drosophila S2 cells, using standard techniques. Briefly,
Balb/c mice were immunized with suPARDIIDIII fragments
conjugated to KLH and the magnitude of the immune response
monitored by ELISA. Based on these data, hybridomas were
generated by fusing spleen cells with the myeloma cell line
P3x63Ag8.653. Frozen stocks of 10 parental hybridomas were
made and five and were purified as described [30]. The SMB
domain protein (amino acid residues 1–50 of human vitronectin)
was a kind gift of Dr. Aiwu Zhou, expressed in of the hybridomas
subjected to limiting dilution. Tissue culture supernatants from
these monoclonal antibodies were then assayed for activity in
ELISA assays and the isotype of each antibody determined using
IsoStrips (Roche).ATN-658, isotype IgG1k, bound suPAR immo-
bilized to plastic with a KD of ,1 nM and iodinated ATN-658
specifically bound uPAR on the surface of HeLa cells with a KD of
,5 nM. The Kd of ATN-658 for suPAR was also confirmed using
surface plasmon resonance (BIAcore). Western blot analysis
demonstrated that ATN-658 was specific for human uPAR and
did not cross-react with mouse uPAR. ATN-658 was purified from
tissue culture supernatant by column chromatography using
protein-A Sepharose, typical yields ranged from 60–120 mg/L
of tissue culture supernatant and the purity of the final material
was .95% as determined by HPLC. Biotin-ATN-658 was
prepared for whole cell binding assays and for flow cytometry as
previously described [27].
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ATN-658 Fab fragments were prepared by extensive proteolytic
digestion of the purified antibody (5 h, 37uC) with immobilized
Papain (Pierce). ATN-658 Fab fragments were separated from the
antibody Fc domains by protein-A affinity chromatography and
the purified Fab fragments characterized by SDS-PAGE. To
confirm that the purified ATN-658 Fab fragments retained the
ability to bind uPAR with high affinity we performed competition
assays using biotinylated ATN-658 [27] and immobilized suPAR.
The protein was concentrated to 5 mg/ml using Millipore
Ultrafree centrifugal filters for protein crystallization.
Evaluation of binding of ATN-658 to cells in vitro
The species specificity of ATN-658 binding was evaluated by
whole cell binding assays or flow cytometry as previously described
[27]. Whole cell binding assays were performed on cells (300,000/
well) plated on gelatin coated 12-well plates (Costar #3516) and
allowed to attach overnight. After extensive washing with Hank’s
buffered salt solution (HBSS; Invitrogen, Inc.) containing 0.1%
bovine serum albumin (BSA; Sigma) adherent cells were incubated
with varying concentrations of biotin-labeled ATN-658 in HBSS/
0.1% BSA for 1 h at room temperature. After washing 3-times
with HBSS/0.1% BSA cells were incubated with HRP-conjugated
streptavidin for a further 0.5 h at RT, wells washed as described
above and bound antibody detected by incubation with OPD
substrate (Sigma). After color development 0.1 mL of substrate
was transferred from each well to a 96 well plate, the reaction
stopped by the addition of 20 mL 1MH2SO4 and the absorbance
at OD-490 nm recorded. Prior to flow cytometry adherent cells
were harvested with trypsin and resuspended in FACS buffer (2%
fetal bovine serum in PBS). Cells (2610
6 cells in 200 mL FACS
buffer) were incubated with ATN-658 (final concentration 10 mg/
mL), control mouse IgG, a rabbit polyclonal antibody (1:100
dilution) raised against a fragment of human uPAR (rDIIDIII) or
normal rabbit serum (NRS) for 1 h at 4uC. Following incubation,
cells were washed three times with 1 mL FACS buffer and
resuspended in 100 mL of FACS buffer containing either goat anti-
rabbit or goat-anti mouse Alexa Fluor 488 conjugated secondary
antibodies (Invitrogen, Inc.) and incubated for 30 minutes at 4uC.
Cells were washed as described above and resuspended in 0.5 mL
FACS buffer prior to acquisition of flow cytometry data.
Site-directed mutagenesis studies of ATN-658 binding to
primate uPAR
African green monkey (AGM) suPAR was cloned from COS-1
cells by PCR, sequenced and the protein expressed as previously
described for human suPAR [30,32]. Site-directed mutagenesis of
the AGM suPAR plasmid template was carried out using a
Quikchange site-directed mutagenesis kit (Stratagene, Inc.),
according to the manufacturer’s instructions, to generate nine
mutants in which each amino acid unique to AGM suPAR was
replaced by the corresponding human suPAR sequence. Sequenc-
ing and restriction digestion of the each mutated plasmid was used
to confirm the sequence change and that the remaining sequence
remained intact. AGM mutant suPAR cDNA was then subcloned
into a Drosophila expression vector (pMT/BiP/V5-HisA) con-
taining the V5 epitope flag and used to transfect S2 cells. Small
scale (500 mL) shaker cultures were established to produce protein
for experiments and protein expression was confirmed by western
blot using a pAb [29] against uPAR that cross-reacted with
primate suPAR. Culture supernatants (CS) for each clone were
clarified by centrifugation and aliquots immune-precipitated using
ATN-658 and protein-G Sepharose. Bound proteins were detected
by western blot using the cross-reacting rabbit anti-DIIDIII
polyclonal antibody described above. Another uPAR MAb, ATN-
615, which is also species specific for human uPAR and for which
the epitope was already known from x-ray crystallography studies
[33,34], was used as a control to validate this IP method.
Alternatively, culture supernatants were analyzed by capture
ELISA using an anti-V5 antibody and biotinylated anti-uPAR
antibodies ATN-658 and ATN-617. ATN-617 [27] is a monoclo-
nal antibody that binds to a different epitope on uPAR and cross-
reacts with AGM suPAR. Plates were coated with V5 antibody
(1 mg/mL) in PBS (100 mL well in a 96 well EIA/RIA high
binding plate). After 3 h incubation at RT, wells were washed and
then incubated with 16casein/water (200 mL/well) for 2 h at RT
to block non-specific binding. Wells were washed and 100 mLo f
culture supernatant was added to each well and incubated O/N at
4uC. Culture supernatants were estimated to contain ,3 ug/mL
of suPAR. Biotin ATN-658 or biotin-ATN-617 (1 mg/mL) was
then added to the wells and incubated for a further 0.5 h at room
temperature followed by extensive washing. Finally, Streptavidin-
HRP was added and after additional incubation and washing,
color was developed using OPD and bound ATN-658 or bound
ATN-617 was detected by absorbance measured at 490 nm, as
previously described [27].
Epitope mapping of ATN-658 by H/D-exchange mass
spectrometry (H/D-Ex)
1.5 mg of ATN-658 Fab fragment was immobilized onto
200 mg POROS AL resin (Applied Biosystems) according to the
manufacturer’s instructions. Pull-down experiments were per-
formed using suPAR-DIIDIII to confirm the specificity and
binding capacity of the affinity column. ATN-658 Fab conjugated
beads (353 mL) were resuspended in 700 mL of deuterated
phosphate buffer (50 mM KH2PO4, 50 mM NaCl, pH 7.4) and
allowed to equilibrate at 4uC.suPAR-DIIDIII was resuspended in
40 mL D2O pH 7.4 (Cambridge Isotopes) for either 150, 500,
1500 or 5000 seconds to allow complete deuteration of surface
amides. Labeled suPAR-DIIDIII and affinity resin were then
mixed together for 10 min at 4uC. Back exchange of solvent
exposed amides was carried out by replacing the
2H phosphate
buffer with H2O and incubating at 4uC for a time equal to the
labeling step. A control experiment was carried out by binding
unlabeled suPAR-DIIDIII to ATN-658 Fab conjugated beads and
labeling the bound material by incubation with 700 mLo f
deuterated phosphate buffer for the times listed above. Back
exchange was then performed as described. The reactions were
quenched and suPAR-DIIDIII eluted from the affinity column
using 40 mL 0.8% formic acid. Following the addition of 20 mL
8 M urea, 1 M TCEP, pH 3.0 the eluted material was injected
into the Hydrogen/Deuterium Exchange Mass Spectrometry (H/
D-Ex) platform (ExSAR, Monmouth Junction, NJ) consisting of
tandem immobilized pepsin and C18 separation columns. The
digested fragments were separated and analyzed by mass
spectrometry and the identities of each peak identified by
comparison with data obtained in control experiments using
deuterium-labeled and unlabeled suPAR-DIIDIII digested with
pepsin.
Protein crystallization and X-ray data collection
The suPAR-ATF complex was formed by incubating ATF with
suPAR at room temperature in 50 mM HEPES and 100 mM
NaCl pH 7.4 and was purified on a Superdex 75 gel filtration
column. The eluted complex was then added excess ATN-658
Fab, and the ternary complex ATN-658-uPAR-ATF was purified
again on a Superdex 200 gel filtration column. Prior to the
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molar ratio, and then concentrated to 10 mg/mL without any
further purification. Crystallization was carried out using the
sitting drop vapor diffusion method at 22uC. The diffracting
quality ATN-658 Fab crystals were generated using 20–22% PEG
3350, 0.1 M Tris pH 8.0–8.5. For crystallization of the ATN-658-
uPAR-ATF-SMB quaternary complex, the protein at 10 mg/mL
was mixed with an equal volume of reservoir solution containing
0.1 M HEPES pH 7.5, 55% (v/v) Tacsimate, and 2% (v/v) 2-
methyl-1,3-propanediol. Triangle crystals were typically appeared
after a couple months and grew to a final size of
0.1560.1560.15 mm
3.
The ATN-658 Fab crystals were cryo-protected with the
addition of 20% glycerol to the mother liquor. Diffraction data
was collected at 100uK on the Advanced Photon Sources
(beamline 22-ID, SER-CAT).X-ray diffraction data collection for
the complex was carried out at 100 K on the NSLS Brookhaven
National Laboratory (beam line 629). Most ATN-658-uPAR-
ATF-SMB quaternary crystals diffracted very weakly, usually less
than 6 A ˚. This is presumably due to high solvent content (76%
solvent) and the presence of a long axis of the crystals
(c=391.58 A ˚). After numerous trials with different crystals,
different data collection strategies and the exploration of different
cryo-protectant solutions. Diffraction data was collected from a
flash-cooled crystal which was cryo-protected by a sequential
soaking into mother liquid with increased concentration of
ethylene glycol to the final concentration of 10% (v/v) to 4.6 A ˚
resolution. The diffraction data were indexed and processed using
the HKL2000 program [35]. The data collection and final
structural refinement statistics for both structures are integrated in
Table 1.
Structure determination and refinement
The structures of the ATN-658 Fab was solved by molecular
replacement method (MOLREP [36]of the CCP4 program suite
[37]) using an antibody structure (PDB entry 2DDQ) as a search
model. The model was then subjected to several rounds of manual
building using Coot [38] alternated with restrained refinement
using Refmac5 [39]. In the final cycles of refinement, TLS with
twenty TLS groups for each chain (generated by the TLS motion
determination (TLSMD) server [40] was included in the
refinement.
This ATN-658 Fab structure was then used as a molecular
replacement model to solve the structure of the quaternary
complex (ATN-658-uPAR-ATF-SMB) by molecular replacement
method using programs MOLREP [36] and CNS [41]. A suPAR-
ATF model (PDB entry 1fd6 [33]) was then positioned into the
crystals of the quaternary complexes by molecular replacement
(molrep [36]). Despite the low resolution of this crystal (4.5 A ˚),
very strong molecular replacement solutions for both models were
obtained. After refinement using the CNS program [41], the Fo-
Fc difference electron density showed the electron density for SMB
domain of vitronectin, further confirming the correct molecular
replacement solutions. The resulting models with all four protein
components were further refined using CNS v1.3 [41]and
Table 1. Statistics of X-ray data collection and structural model refinement.
Crystals ATN 658 Fab ATN-658-uPAR-ATF-SMB
X-ray source APS SER-CAT beamline 22-ID BNL 629
Temperature (K) 100 100
Resolution range 31.45-1.60 (1.64-1.60)
a 26.90- 4.50 (4.66-4.50)
a
Wavelength (A ˚) 1.04 1.04
Space group P1211 H32
Cell parameters (A ˚) 37.31, 132.30, 46.83 164.65, 164.659, 391.582
Unique reflections 49312 (4021) 12451 (1221)
Rmerge (%)
b 0.094 (0.290) 0.139 (0.841)
Completeness (%) 85.7(70.0) 99.7(100.0)
Average I/s 9.2 (4.65) 16.14 (2.03)
Data redundancy 3.0 (2.6) 4.4 (4.5)
Model refinement:
R-factor/Rfree (%) 19.8/24.6 20.7/29.3
Overall B-factors (A ˚ 2) 23.0 61.436
Protein B-factors (A ˚ 2) 21.3 259.694
Solvent B-factors (A ˚ 2) 39.4
R.m.s.d. from ideal bond length (A ˚) 0.012 0.013
R.m.s.d from ideal bond angles (6) 1.407 2.018
Ramachandran plot, % residues in regions:
favored 93.8 84.5
allowed 5.7 13.7
outlier 0.5 1.8
PDB ID
aNumbers in the parentheses are for the highest resolution shells;
bRmerge=ShSi|Ii(h)-,I(h).|/ShSiIi(h), where ,I(h). is the mean intensity of reflection h.
doi:10.1371/journal.pone.0085349.t001
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Coot [38].
All final structures were analyzed and validated by PRO-
CHECK [43], PYMOL [44] and MOLSOFT ICM [45]. The
coordinates of the reported structure have been deposited in the
Protein Data Bank (PDB). The final statistics, validation, and
stereochemical quality for the structure are reported in Table 1.
Co-immunoprecipitation
HT1099 cells were lysed in Triton lysis buffer (50 mMHepes,
pH 7.5, 150 mM NaCl, and 1% Triton X-100) supplemented
with protease inhibitors and 1 mM PMSF. Clarified lysates were
immunoprecipitated with antibodies ATN-615 and ATN-658.
The immunoprecipitates were blotted for uPAR (R2) or integrin
a5 (pAb).
Cell adhesion assay
The cell adhesion assay was performed as described previously
[46]. In brief, H1299 cells were incubated in DME/0.1% BSA
with 500 mM RGD or RAD peptides for 1 h at 37uC and were
then seeded onto fibronectin (5 mg/ml, Sigma)–coated plates with
or without ATN-615. After washing, attached cells were fixed and
stained with Giemsa. The data were quantified by measuring
absorbance at 550 nm.
Results
ATN-658 does not bind to non-human uPAR
Initial studies evaluated the binding of ATN-658 to cells from
various species that expressed uPAR. uPAR expression was
confirmed in all cell lines initially by RT-PCR followed by
western blot using a rabbit anti-human uPAR pAb (rD2D3) that
cross-reacts with uPAR from rodent and dog. This study was
undertaken to identify possible animal species that could be used
for future toxicology studies of ATN-658. Biotin-ATN-658, which
retained the full binding activity of unmodified ATN-658 [27], was
used for this evaluation. Biotin-ATN-658 did not bind to mouse
melanoma (B16) cells (Fig. 1A) or African green monkey (AGM)
(Fig. 1B) immortalized kidney cells (COS-1) in whole cell
saturation binding experiments, whereas saturable binding was
observed to the uPAR expressing human prostate cancer cell line,
Figure 1. Cross reactivity of ATN-658 with uPAR from various species. A & B. The specificity of ATN-658 was measured by direct binding
assays using uPAR expressing mouse melanoma (B16), human prostate carcinoma (PC-3) and African green monkey (COS-1) cells and biotin-labeled
ATN-658. B. FACS analysis was performed using HeLa cells (expressing human uPAR), D-17 lung carcinoma cells (expressing canine uPAR and COS-1
cells. Each cell line was incubated with normal rabbit serum (NRS), a rabbit polyclonal antibody raised against a fragment of human uPAR (rDIIDIII),
mouse IgG (mIgG) or ATN-658 and the appropriate FITC labeled secondary antibody.
doi:10.1371/journal.pone.0085349.g001
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confirmed and extended to include dog osteosarcoma cells (D-17)
using non-biotinylated ATN-658 and an isotope matched IgG as a
negative control and evaluated by flow cytometry (Fig. 1C).
Identification of the epitope for ATN-658 on human
suPAR by site-directed mutagenesis
Sequence alignment of primate DIIDIII uPAR sequences
revealed that human and AGM uPAR only differed at nine
amino acid positions (Table 2). These nine amino acid differences
were sufficient to completely abrogate the binding of ATN-658 to
AGM uPAR. Thus, we cloned and expressed AGM suPAR in S2
cells and made nine different mutants that sequentially replaced
one amino acid from the AGM sequence in each mutant with the
corresponding human amino acid (Fig. 2A). The initial evaluation
of these mutants was qualitative where the ability of ATN-658 to
immunoprecipitate (IP) a particular mutant from the culture
supernatant (CS) from cells expressing that mutant was assessed.
ATN-615, which is also human uPAR specific but for which we
had already identified the epitope [33,34], was used to confirm the
utility of this approach. ATN-615 was only able to IP the H192R
suPAR mutant (clone 2; Fig. 2A). This is consistent with the
described epitope for ATN-615, which is comprised of aa 187–192
(Fig. 2A). In fact, the only amino acid difference between AGM
and human uPAR in this epitope is at aa 192. Similarly, ATN-658
was only able to IP the E268K (clone 8) suPAR mutant implicating
this residue as part of the ATN-658 epitope. Alanine scanning
mutagenesis around this amino acid maps out the sequence from
aa 268–275 as the epitope for ATN-658 (S1). Since IP is a
qualitative assessment of binding, capture ELISA assays were set
up to measure the actual affinity of ATN-658 for the various AGM
suPAR mutants as it was possible that perhaps more than aa 268
was required in order to restore full binding activity for ATN-658
Figure 2. Immunoprecipitation of AGM suPAR clones using ATN-615 and ATN-658. A. Single point mutants were introduced into AGM
suPAR such that a single amino acid was changed from the AGM sequence to the human uPAR sequence and the proteins expressed and purified as
described in the Materials and Methods. Each clone is identified by number (1–9) with the point mutation identified below the number using the
single letter amino acid code. Except for the single point mutation, the rest of the suPAR sequence is that of AGM. suPAR mutants were expressed in
S2 cells and supernatants incubated with either ATN-615 or ATN-658 followed by immunoprecipitation as described in Materials and Methods. suPAR
was then detected by western blot using a rabbit polyclonal antiserum raised against human suPAR. B. Capture ELISA assays were used to measure
the binding affinity of ATN-658 for the various suPAR clones described in (A). Capture on the ELISA plate was through the V5 tag and detection used
biotin-ATN-658. C. Biotin-ATN-617 was used in a similar ELISA format as described in (B) to confirm that introduction of the single point mutation did
not have a global effect on suPAR conformation.ATN-617 cross-reacts with monkey suPAR and all clones appeared to retain this reactivity after
introduction of the mutation.
doi:10.1371/journal.pone.0085349.g002
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sequence. Since the AGM suPAR mutants were expressed with an
incorporated V5 flag, an anti-V5 flag antibody was used to capture
AGM suPAR on solid phase. The binding affinity could then be
determined for each AGM mutant using saturation binding studies
as previously described for ATN-658 [27]. Using this approach,
the binding of ATN-658 was only observed to clone 8 with a
Kd,2 nM, similar to the Kd of ATN-658 for human suPAR and
for human uPAR expressing cells indicating that this single amino
acid change was responsible for complete abrogation of ATN-658
binding to AGM suPAR (Fig. 2B). This single amino acid change
did not abrogate ATN-658 binding through a global effect on
suPAR conformation since the binding of ATN-617, which binds
to DIIDIII and does cross-react with AGM suPAR, was not
altered (Fig. 2C).
Alignment of this epitope across multiple species of uPAR helps
explain the species specificity of ATN-658 binding (3). The old
world primates (apes, chimpanzees) are evolutionarily nearer to
man and have homologous uPAR to human in the epitope for
ATN-658. ATN-658 binding has been observed by immunohis-
tochemistry to chimpanzee tissues consistent with this observation.
In contrast, new world primate (macaques, AGM) uPAR differs in
most cases at a single residue, aa 268, and this is sufficient to
completely abrogate the binding of ATN-658. The uPAR of lower
order mammals also differs at this position as well as others
consistent with the lack of binding of ATN-658 to uPAR or cells
expressing uPAR from these species as well (Table 3).
Confirmation of ATN-658 epitope by Hydrogen/
Deuterium Exchange Mass Spectrometry (H/D-Ex)
Hydrogen-deuterium (
1H-D) exchange is a useful tool for
identifying protein binding sites or interfaces. Following transfer
from water to a deuterium-based solvent system (heavy water) a
protein will experience an increase in mass as the protein
hydrogen atoms are gradually replaced with deuterons. The
likelihood of a hydrogen-deuterium exchange event is largely
determined by protein structure and solvent accessibility. Differ-
ences in the rate of amide hydrogen exchange identify the location
of an epitope. When an antibody binds to a protein target, surface
regions that exclude solvent upon complex formation exchange
much more slowly. Thus, solvent excluded regions are useful for
deducing the location of a binding site. Using this approach,
1H-D
exchange was measured for DIIDIII suPAR with and without
ATN-658 bound as described in Methods and a difference map
determined (Fig. 3). Differences in
1H-D exchange in blue
demonstrated no difference between bound and unbound DIIDIII
suPAR whereas differences in green suggested at least a 40%
difference in exchange and identified the epitope of ATN-658 on
suPAR. The only sequence where this difference was observed in
the presence of ATN-658 was between aa 268–277 (Fig. 3),
confirming the epitope identified using site directed mutagenesis.
Table 2. Amino acid sequence differences in DIIDIII of uPAR from human, African green monkey (AGM) and cynomolgus monkey
(crab eating macaque).
suPAR Amino Acid # Human
Cercopithecus aethiops (African
Green monkey COS-1)
Macaca fascicularis (Crab eating or
Long tailed Macque)
125 V M V
152 G G S
157 N N S
192 R H H
229 H Y Y
242 A V V
249 H R R
259 N N H
262 D N N
264 S F S
268 K E E
278 V V I
282 S K K
doi:10.1371/journal.pone.0085349.t002
Table 3. Sequence alignment of the ATN-658 epitope in
primates and lower order mammals.
268 277
Human KSGCNHPDLD
Bonobo KSGCNHPDLD
Chimpanzee KSGCNHPDLD
Gorilla KSGCNHPDLD
Orangutan KSGCNHPDLD
Pigtailed Macaque ESGCNHPDLD
Rhesus Macaque ESGCNHPDLD
Long-tailed Macaque ESGCNHPDLD
African Green Monkey ESGCNHPDLD
Ring-tailed LEmur GSGCNHPARD
Northern Owl Monkey ENDCNNPAED
Dog TGNSCNHPILD
Mouse HGSGCNSPTGG
Rat NGSGCNRPTGG
Hamster DGDGCNGPRSG
A single amino acid change in this epitope is sufficient to confer species
specificity of ATN-658 for human uPAR.
doi:10.1371/journal.pone.0085349.t003
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with uPAR, ATF and SMB reveal the binding epitope of
ATN-658
To further evaluate the binding epitope of ATN-658, we
determined the crystal structure of ATN-658 and its complex with
human soluble uPAR. We crystallized the quaternary complex of
ATN-658, suPAR, ATF, and somatomedin B domain (SMB) of
vitronectin. The presence of the SMB was absolutely necessary to
obtain the protein crystals. The crystals diffracted to only 4.5 A ˚,
despite numerous optimization efforts on protein crystallization
and X-ray data collection strategies. This is presumably due to
high solvent content (76% solvent) and the presence of a long axis
in the crystals (c=391.58 A ˚).In order to solve this low resolution
structure using molecular replacement, we also crystallized the free
Fab fragment of ATN-658, and determined its structure to a high
resolution (1.6 A ˚, Table 1). This structure of ATN-658 Fab
fragment, together with the structures of uPAR-ATF-SMB [47],
allowed us to unambiguously solve the quaternary structure of
ATN-658-uPAR-ATF-SMB using molecular replacement meth-
ods (Table 1).
The 1.6 A ˚ crystal structure of the ATN-658 Fab alone consists
of residues 1–127 and 134–212 of the heavy chain and residues 1–
213 of the light chain. The antigen-binding site located at the end
of the variable domains, comprised of six CDRs, is clearly defined
in this antigen-free structure. The H3 loop lies in the center of the
pocket surrounded by the light-chain CDRs L1, L2, and L3 and
the heavy-chain CDRs H1 and H2, with both hydrophobic and
hydrophilic interactions with the other CDRs. The six CDRs form
a relatively flat but undulating surface, a feature of anti-protein
antibodies. In addition, the conformations of the 6 CDRs in the
free form are quite similar to the conformations in the antigen-
bound form (RMSD of 0.49 A ˚ for Ca atoms in 427 residues).
These results indicate that ATN-658 has structurally rigid CDRs.
Despite the limited resolution of 4.5 A ˚, the ATN-658-uPAR-
ATF-SMB quaternary complex has high quality. The inherent
glycans of uPAR at amino acid residue 52, 172, and 200 were
clearly visible in the 2Fo-Fc electron density map. Three N-
acetylglycosamine glycan residues were built into a large piece of
electron density around the uPAR glycosylation site at residue 52.
This is the largest glycan structure observed so far among all the
published uPAR-ligand structures at this position. Besides the
antibody, the other three components in the quaternary complex,
uPAR-ATF-SMB, adopt the same conformation as previous
published structures (3BT1 and 3BT2) [47] with an overall
RMSD of 0.8 A ˚. ATF binds in the central pocket of the receptor
comprised of all of three domains [33]. The SMB binds to the
outer side of the DI b sheet, and also to part of the DII domain
[47]. Both the ATF and SMB are located on the top of the
receptor (Fig. 4), but without direct overlap between them. Crystal
packing shows that ATF and SMB from one complex intertwined
into the cleft formed by the ATF and SMB from another
symmetry-related ATN-658-uPAR-ATF-SMB complex with hy-
drophilic and hydrophobic interactions. The buried area between
these two complexes is quite large (3033 A ˚ 2). This extensive crystal
contact of the SMB explains the requirement for the SMB to
generate the current crystal form.
The structure of ATN-658-uPAR-ATF-SMB quaternary com-
plex corroborates the biochemical mapping studies but also reveals
several unexpected features of both the epitope and ATN-658
itself. The epitope of ATN-658 is restricted to the DIII domain at
the bottom (near the C-terminus) of the receptor (Fig. 4), and
consists of three segments of the uPAR DIII domain: 1) the C-
terminal segment of uPAR (residues Gly270, His273, and Asp275);
2) uPAR DIII domain b strand IIIA (residues Gln193 and
Tyr195); and 3) uPAR DIII domain b strand IIIA (residues
Phe211, Leu212 and Asp214). Among these three segments, the
C-terminal segment of uPAR has direct interaction to CDR H3
loop of ATN-658 and appears to be the most important epitope
for antibody recognition. These results are consistent with the
alanine scanning mutagenesis results (Fig. 2) and the alignment of
non-primate of uPAR sequence (Table 3). On the ATN-658 side,
both the heavy and light chains of ATN-658 are involved in
antigen binding. However, the heavy chain CDR are the primary
structural determinants that recognize suPAR. The light chain
CDR play a minor role in the binding, recognizing only the last C-
terminal residue of uPAR, Asp275. Such recognition modes
Figure 3. EXSAR difference map between ATN-658 bound and free suPARDIIDIII. EXSAR analysis was carried out as described in Material
and Methods.
doi:10.1371/journal.pone.0085349.g003
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antigen complexes [48,49].
ATN-658 has structural and sequence homology to the
uPAR binding region of CD11b(aM) and inhibits binding
to a5b1 and RGD mediated adhesion to fibronectin
We found that short stretches of the ATN-658 CDR sequences
(H2, H3, L1, L3) align and have a high degree of homology with
the b-propeller domain of the integrin, CD11b (aM) (loops 1, 2,
and 3, Fig. 5A). In addition, the spatial arrangements of these
loops also superimpose well in three-dimensions, based on the
current ATN-658 crystal structure and a homology structure
model of aMb2 (Fig. 5B). It would have been very difficult to
detect this homology based on the alignment of linear amino acid
sequences since these short stretches of amino acids assemble from
the various CDR loops only in the three-dimensional structure of
ATN-658 bound to suPAR. This suggests that ATN-658 may be
an antagonist of the aMb2-uPAR interaction. Further experi-
mental verification is currently underway.
We also found that ATN-658 blocks the interaction of uPAR
with another integrin, a5b1. ATN-658 and a control anti-uPAR
antibody, ATN-615, both in IgG and Fab forms, were used to
immunoprecipitate (IP) uPAR from cell lysates of H1299, a human
non-small lung carcinoma cell line that expresses high levels of
uPAR. The resulting immunoprecipitates were analyzed by
Western blot for uPAR and a5 integrin subunits. ATN-615 was
able to IP both uPAR and a5 integrin (Fig. 6A). However, ATN-
658 was only able to IP uPAR, but not a5, and thus appears to
block the interaction of uPAR with a5 integrin. To validate this
result, a fibronectin adhesion assay was carried out. Adhesion of
H1299 cells to fibronectin is mediated to a large extent by the
a5b1 integrin and this adhesion can be completely blocked by an
a5b1-blocking antibody (5H10-27) [29,50]. This a5b1-mediated
fibronectin adhesion can also be abrogated by an integrin binding
RGD peptide. However, we observed that uPAR over-expression
in H1299 cells can antagonize the effect of the RGD peptide, and
increase cell adhesion to fibronectin in the presence of RGD-
containing peptides [50]. Based on this uPAR-enhanced adhesion
and other observations, uPAR was proposed to interact with the
bent conformation of integrin a5b1 and render it capable of
Figure 4. X-ray structure of ATN-658-uPAR-ATF-SMB tertiary structure. (A) The 1.6 A ˚ structure of the ATN-658 Fab at two orthogonal views.
Light chain is shown in light blue and heavy chain in dark blue. (b) Stereo view of the ATN-658 Fab in complex with suPAR (magenta) in the presence of
ATF (cyan) and SMB (green) of vitronectin. All figures were made by PyMOL. (c) Interaction of uPAR–ATN-658 Fab in stereoview. Selected contacting
residues in stick representation; hydrogen bonds are shown in dashed lines. (d) Open-book view of the interface between suPAR (left) and atn658 Fab
(right). The Fab heavy and light chains are pink and yellow, respectively, whereas the suPAR, ATF and SMB are rose, green and cyan, respectively. The
bindinginterfacebetweensuPARandFabarecoloredasredforatn658,blue foratn615andorangefortheoverlappingepitopeofthesetwoantibodies.
doi:10.1371/journal.pone.0085349.g004
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adhesion is completely inhibited by ATN-658, but not by control
IgG or ATN-615 (Fig. 6B). This suggests that ATN-658 can also
block the uPAR-a5b1 interaction which was unexpected since the
region of uPAR that has been implicated in the a5b1 interaction
resides between aa 240–248 [15] whereas ATN-658 binds to aa
268–275. However, previous studies using a peptide derived from
aM (M25) that inhibited the uPAR-aM interaction [51] demon-
strated that inhibiting the uPAR-aM interaction on leukocytes also
blocked the uPAR-a5b1 interaction, which suggests that ATN-658
may broadly impact uPAR-integrin interactions.
Discussion
In this study, we have identified an epitope in uPAR with a
previously unrecognized function that serves as the binding site for
the novel therapeutic uPAR antibody, ATN-658. Over the past
several decades, several uPAR antibodies have been identified that
bind to human uPAR with high affinity. However, ATN-658 is the
first uPAR antibody to demonstrate consistent robust antitumor
effects across a variety of tumor models [22,26–28] that include
not only inhibition of invasion and metastasis but also inhibition of
proliferation and induction of apoptosis. The epitope for ATN-
658, aa 268–277 of uPAR, resides in DIII and contains a small 6-
mer disulfide loop near the glycolipid anchor of uPAR. Another
anti-uPAR antibody, ATN-615, also binds to the DIII domain of
uPAR [34], but does not show any antitumor effects in vitro or in
vivo. This non-inhibitory antibody recognizes a different non-
overlapping set of epitope residues compared to ATN-658 and
emphasizes the importance of targeting the correct uPAR epitope
for cancer therapy. We have also evaluated other uPAR antibodies
that block uPA binding to uPAR (e.g. ATN-617) in various tumor
models and these also have poor antitumor effects in vivo. Based on
these observations, ATN-658 has now been humanized (huATN-
658) and a first-in-man study is being planned for the near future.
Figure 5. Sequence and 3-dimensional structural similarity between aM binding loops and ATN-658 CDR loops. (A) Sequence
alignment of integrin aM loops to ATN-658 CDR loops. (B) Similar spatial arrangement between integrin aM loops and the ATN-658 CDR loops.
Structure of aM was a homology model built from the known integrin structures (http://prosite.expasy.org/cgi-bin/pdb/get-pdb.pl?1a8x).
doi:10.1371/journal.pone.0085349.g005
Figure 6. ATN-658 inhibits a5b1 mediated binding to uPAR and adhesion to fibronectin. (A) ATN-658, but not ATN-615, inhibits coIP of
uPAR with a5. HT1080 cells were lysed in 1% Triton X-100 lysis buffer and the lysates were immunoprecipitated with indicated antibodies, followed
by separation on SDS-PAGE and blotting for uPAR (R2) and integrin a5. Data shown are representative of three independent experiments. White lines
indicate that intervening lanes have been spliced out. (B) ATN-658, but not ATN-615, interferes with H1299 uPAR-expressing cells adhesion on Fn in
the presence of RGD peptide. H1299 cells pre-treated with RGD or RAD peptides (500 mM) were seeded onto Fn-coated 96-well plates together with
antibodies ATN-615 or ATN-658. After incubation for 1 hr at 37uC, plates with triplicate determinations were washed, and attached cells were fixed
and stained with Giemsa. All the above experiments were performed at least three times with similar results.
doi:10.1371/journal.pone.0085349.g006
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exerts its antitumor effects at the molecular level. The observation
that the interaction of ATN-658 with uPAR closely mimics that of
CD11b (aM; Mac-1; CR3) with uPAR has broad implications for
the role of uPAR in tumor progression. aM forms a heterodimer
with b2( aMb2) and is expressed on the surface of many leukocytes
involved in the innate immune system [52,53]. aMb2 mediates
inflammation by regulating leukocyte adhesion and migration
[52,53]. Recently, CD11b expression has been demonstrated to
define a subpopulation of bone marrow derived myeloid cells
(BMDC) that seed the pre-metastatic niche and without which
tumor metastasis is unable to progress [54]. The CD11b positive
BMDC may actually encompass several subpopulations of cells,
some of which act as suppressors to dampen cytotoxic T cell
response and therefore allow tumors to progress [55]. In addition,
CD11b-positive cells may secrete factors that drive tumor
progression and subpopulations have also been demonstrated to
be involved in tumor resistance to anti-angiogenic therapy [56].
Historically, uPAR has been implicated in the metastatic
process and conceptually, this implication has focused on its role
in invasion and migration prior to intravasation or during the
process of extravasation but not once cells have extravasated and
seeded a metastatic site. The fact that ATN-658 mimics the
CD11b-uPAR interaction suggests that ATN-658 may block this
interaction and suggests several hypotheses as to how uPAR may
actually function to promote metastasis. When treating a patient
with advanced cancer, it needs to be assumed that metastases are
already present when treatment is started even if they are not
detected radiographically. Thus, inhibiting the progression of
established metastases may be more therapeutically relevant than
trying to interfere with the metastatic process. If the uPAR-CD11b
interaction is central to metastatic outgrowth, ATN-658 may be
targeting the most clinically relevant and actionable aspect of
metastasis.
This study leads to several hypotheses of how uPAR-CD11b
may promote metastasis. One hypothesis is that uPAR on a tumor
cell may interact with CD11b on a leukocyte in the pre-metastatic
niche in trans and this interaction may mediate survival and
outgrowth of the uPAR expressing tumor cells, possibly by
dampening T cell or innate immune response at the metastatic
site. An alternative hypothesis is that CD11b is expressed directly
on a tumor cell so that uPAR and CD11b interact in cis. The
contribution of each of these interactions to tumor progression and
the molecular mechanisms that are downstream of uPAR-CD11b
binding remain to be elucidated and are a major focus for future
studies.
In our study, we also observe the ability of ATN-658 to inhibit
the interaction of uPAR with a5b1 in H1299 tumor cells as well as
antagonize RGD mediated anti-adhesive effects of tumor cells
interacting with fibronectin (Fig. 6). Although we cannot rule out a
steric effect of ATN-658 on the uPAR interaction with a5b1, we
hypothesize that ATN-658 may alter global integrin clustering and
signaling through the inhibition of the CD11b-uPAR interaction.
In that regard, a peptide, M25, that blocked the uPAR-CD11b
interaction was demonstrated to also inhibit the interaction of
uPAR with b1 integrins (32). In addition, we also demonstrate that
ATN-658 blocks CD11b mediated adhesion of U937 cells. Our
previous studies using both unbiased and biased approaches
demonstrated that ATN-658 inhibits integrin signaling in vitro and
in vivo as well as co-localization of a5b1 and uPAR [22,27]. Our
data suggest that the effects of ATN-658 on perturbing the uPAR-
a5b1 interaction is indirect and direct binding of uPAR to integrin
a5b1 or any other integrin using purified components has not
been demonstrated [57], suggesting that these interactions require
multiple components present at the cell surface. The existence of a
signalosome containing uPAR has been postulated by D’Allessio
and Blasi [58] and the data obtained to date supports the
hypothesis that ATN-658 disrupts the signalosome leading to
Figure 7. Schematic of ATN-658 disruption of uPAR signalosome.
doi:10.1371/journal.pone.0085349.g007
Novel uPAR Epitope Involved in Tumor Progression
PLOS ONE | www.plosone.org 11 January 2014 | Volume 9 | Issue 1 | e85349global effects on integrin signaling and inhibition of tumor
progression (Fig. 7). uPAR may behave as a scaffolding protein
in the assembly of this signalosome. Although the exact temporal
order and sets of interactions that mediate these effects remain to
be elucidated, these observations strongly support uPAR as a
global mediator of integrin signaling and interactions as well as a
cancer target that will affect multiple tumor progression pathway
[22,26–28].
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